Pharming Group (PHAR)

• Market cap: $659M
• 1 day: 0.00%
• 5 days: 1.68%
• 1 month: 11.10%
• 3 months: 10.59%
• 6 months: 17.27%
• Year to date: -7.17%
• 1 year: -25.31%
• 5 years: -41.86%
• 10 years: -41.86%

About: Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.

Employees: 382

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

45% more capital invested

Capital invested by funds: $254K [Q2] → $369K (+$115K) [Q3]

0% more funds holding

Funds holding: 5 [Q2] → 5 (+0) [Q3]

0% more ownership

Funds ownership: 0.01% [Q2] → 0.01% (+0%) [Q3]

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $14 44% upside
• Avg. target: $27 178% upside
• High target: $37 281% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Joseph Pantginis 32% 1-year accuracy 124 / 389 met price target	281% upside $37	Buy Reiterated	17 Dec 2024
Jefferies Lucy Codrington 100% 1-year accuracy 1 / 1 met price target	44% upside $14	Buy Initiated	9 Dec 2024
Oppenheimer Michael Carrier 100% 1-year accuracy 6 / 6 met price target	209% upside $30	Outperform Maintained	28 Oct 2024